As of 2024-12-11, the Fair Value of Newron Pharmaceuticals SpA (NWRN.SW) is -4.49 CHF. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 7.71 CHF, the upside of Newron Pharmaceuticals SpA is -158.28%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -20.21 | -21.00 | -14.90 | -17.49 | -16.22 | -17.96 |
| YoY growth | -34.40% | -3.91% | 29.04% | -17.39% | 7.25% | -3.88% |
| Market Cap (mil) | 150.03 |
| P/E | |
| Forward P/E |
| EPS | -0.97 |
| Avg earnings growth rate | -3.88% |
| TTM earnings | -18.83 |